ziritaxestat   Click here for help

GtoPdb Ligand ID: 9561

Synonyms: compound 11 [PMID: 28414242] | GLPG-1690 | GLPG1690
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Ziritaxestat (GLPG1690) is a selective autotaxin Inhibitor [3], that was investigated for anti-fibrotic efficacy. Animal studies using GLPG1690 suggested potential for autotaxin inhibition in breast cancer treatment [2,9] and TSC2-loss associated oncogenicity (in tuberous sclerosis complex) [4]. In early 2021 data from the phase 3 ziritaxestat program in idiopathic pulmonary fibrosis (IPF; ISABELA) was analysed, and the conclusion reached was that ziritaxestat's benefit-risk profile did not support continuing the program. At that time the decision was made to discontinue the inhibitor's phase 2 trial in systemic sclerosis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 132.48
Molecular weight 588.24
XLogP 3.62
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCc1nc2n(c1N(c1sc(c(n1)c1ccc(cc1)F)C#N)C)cc(cc2C)N1CCN(CC1)CC(=O)N1CC(C1)O
Isomeric SMILES CCc1nc2n(c1N(c1sc(c(n1)c1ccc(cc1)F)C#N)C)cc(cc2C)N1CCN(CC1)CC(=O)N1CC(C1)O
InChI InChI=1S/C30H33FN8O2S/c1-4-24-29(35(3)30-34-27(25(14-32)42-30)20-5-7-21(31)8-6-20)39-15-22(13-19(2)28(39)33-24)37-11-9-36(10-12-37)18-26(41)38-16-23(40)17-38/h5-8,13,15,23,40H,4,9-12,16-18H2,1-3H3
InChI Key REQQVBGILUTQNN-UHFFFAOYSA-N
Bioactivity Comments
GLPG1690 produces a sustained decrease in plasma LPA levels in vivo and this results in reduced extracellular matrix deposition in the lung tissue of mice with bleomycin-induced pulmonary fibrosis [3]
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
autotaxin Primary target of this compound Hs Inhibitor Inhibition 7.8 pKi - 3
pKi 7.8 (Ki 1.5x10-8 M) [3]
Description: Inhibition of substrate (LPC) conversion to LPA.